Candel Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| MARCH 31,2025(Unaudited) | DECEMBER 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $92,165 | $102,654 |
| Prepaid expenses and other current assets | 983 | 1,150 |
| Total current assets | 93,148 | 103,804 |
| Fixed assets, net | 1,965 | 2,191 |
| Lease right of use assets | 468 | 542 |
| Restricted cash | 266 | 266 |
| Other assets | 58 | 63 |
| Total assets | $95,905 | $106,866 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $760 | $237 |
| Accrued expenses | 2,720 | 5,113 |
| Current portion of term loan payable to a bank | 9,172 | 9,895 |
| Current portion of lease liability | 580 | 566 |
| Warrant liability | 6,837 | 21,718 |
| Total current liabilities | 20,069 | 37,529 |
| Term loan payable to a bank | — | 1,733 |
| Other long-term debt | 904 | 870 |
| Lease liability, net of current portion | 257 | 407 |
| Total liabilities | 21,230 | 40,539 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued or outstanding at March 31, 2025 and December 31, 2024, respectively. | — | — |
| Common stock, $0.01 par value; 150,000,000 shares authorized at March 31, 2025 and December 31, 2024; 49,369,749 and 46,933,088 shares issued at March 31, 2025 and December 31, 2024, respectively; 49,247,141 and 46,810,480 shares outstanding at March 31, 2025 and December 31, 2024, respectively. | 493 | 469 |
| Treasury stock (at cost) | (448) | (448) |
| Additional paid-in capital | 259,456 | 258,511 |
| Accumulated deficit | (184,826) | (192,205) |
| Total stockholders’ equity | 74,675 | 66,327 |
| Total liabilities and stockholders’ equity | $95,905 | $106,866 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.